These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 6694694)

  • 1. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    Nutt JG; Woodward WR; Hammerstad JP; Carter JH; Anderson JL
    N Engl J Med; 1984 Feb; 310(8):483-8. PubMed ID: 6694694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
    Mouradian MM; Juncos JL; Fabbrini G; Chase TN
    Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
    Fabbrini G; Mouradian MM; Juncos JL; Schlegel J; Mohr E; Chase TN
    Ann Neurol; 1988 Sep; 24(3):366-71. PubMed ID: 3228270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.
    Nutt JG
    Ann Neurol; 1987 Oct; 22(4):535-40. PubMed ID: 3324948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-O-methyldopa and the response to levodopa in Parkinson's disease.
    Nutt JG; Woodward WR; Gancher ST; Merrick D
    Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary method for reducing fluctuations in Parkinson's disease.
    Pincus JH; Barry KM
    Yale J Biol Med; 1987; 60(2):133-7. PubMed ID: 3577210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
    Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease].
    Sanchís G; Mena MA; Martín del Río R; Morales B; Casarejo MJ; de Yébenes MJ; Tabernero C; Jiménez A; de Yébenes JG
    Arch Neurobiol (Madr); 1991; 54(6):296-302. PubMed ID: 1811460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI; Mark MH
    Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease.
    Sage JI; Schuh L; Heikkila RE; Duvoisin RC
    Clin Neuropharmacol; 1988 Feb; 11(1):36-44. PubMed ID: 3349496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Chase TN
    Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of protein-restricted diet on motor response fluctuations in Parkinson's disease].
    Hirata H; Asanuma M; Kondo Y; Ogawa N
    Rinsho Shinkeigaku; 1992 Sep; 32(9):973-8. PubMed ID: 1300270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
    Baronti F; Ruggieri S; Mouradian MM; Bonamartini A; Bocciarelli P; De Pandis MF; Chase TN; Agnoli A
    Riv Neurol; 1991; 61(6):210-4. PubMed ID: 1813972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
    Hutton JT; Morris JL
    Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical aspects of motor fluctuations in Parkinson's disease.
    Poewe WH
    Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea.
    Sage JI; Mark MH; McHale DM; Sonsalla PK; Vitagliano D
    Ann Neurol; 1991 Jun; 29(6):623-8. PubMed ID: 1892365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion.
    Meiler B; Andrich J; Müller T
    Mov Disord; 2008 Jan; 23(1):145-6. PubMed ID: 17987653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.